| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $29,281,576 | 1,615,981 | Commodore Capital LP | 08 Aug 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.5% | $28,392,908 | 1,530,615 | RA Capital Management, L.P. | 11 Aug 2025 | |||
| JANUS HENDERSON GROUP PLC | 8.2% | $44,444,160 | 1,341,508 | JANUS HENDERSON GROUP PLC | 28 Nov 2025 | |||
| Farallon Capital Partners, L.P. | 7.3% | $20,666,041 | 1,140,510 | Dapice Joshua J. | 08 Aug 2025 | |||
| Schornstein Alexander | 3.5% | -65% | $10,082,352 | -$3,424,144 | 543,523 | -25% | Alexander Schornstein | 11 Aug 2025 |
| ARMISTICE CAPITAL, LLC | 10% | $5,252,553 | 289,876 | Armistice Capital, LLC | 30 Jun 2025 |
As of 30 Sep 2025, 56 institutional investors reported holding 12,244,439 shares of ASSEMBLY BIOSCIENCES, INC. - Common Stock (ASMB). This represents 75% of the company’s total 16,359,854 outstanding shares.
The largest institutional shareholders of ASSEMBLY BIOSCIENCES, INC. - Common Stock (ASMB) together control 73% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 28% | 4,505,391 | +104% | 6.4% | $115,338,010 |
| FARALLON CAPITAL MANAGEMENT LLC | 7.5% | 1,227,590 | 0.18% | $31,426,304 | |
| RA CAPITAL MANAGEMENT, L.P. | 6.2% | 1,020,410 | 0.32% | $26,122,496 | |
| Commodore Capital LP | 6.1% | 1,000,000 | 1.2% | $25,600,000 | |
| JANUS HENDERSON GROUP PLC | 4.6% | 752,626 | 0.01% | $19,225,831 | |
| VANGUARD GROUP INC | 3.1% | 502,112 | +98% | 0% | $12,854,067 |
| Frazier Life Sciences Management, L.P. | 2.8% | 456,249 | 0.35% | $11,679,974 | |
| Blackstone Inc. | 2.7% | 447,789 | 0.05% | $11,463,398 | |
| Point72 Asset Management, L.P. | 1.8% | 296,017 | 0.02% | $7,578,042 | |
| Parkman Healthcare Partners LLC | 1.5% | 250,981 | 0.71% | $6,425,114 | |
| B Group, Inc. | 1.1% | 175,706 | -7.2% | 4.3% | $4,498,074 |
| BlackRock, Inc. | 1% | 170,199 | +90% | 0% | $4,357,094 |
| RENAISSANCE TECHNOLOGIES LLC | 0.94% | 153,611 | +43% | 0.01% | $3,932,442 |
| Patient Square Capital LP | 0.83% | 135,182 | 0.93% | $3,460,659 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.8% | 131,026 | 0% | $3,354,266 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.8% | 130,095 | +155% | 0% | $3,331,113 |
| Schonfeld Strategic Advisors LLC | 0.75% | 121,888 | 0.02% | $3,120,330 | |
| MARSHALL WACE, LLP | 0.52% | 85,215 | 0% | $2,181,504 | |
| STEMPOINT CAPITAL LP | 0.4% | 66,130 | 0.34% | $1,692,928 | |
| CITADEL ADVISORS LLC | 0.33% | 53,878 | +51% | 0% | $1,379,277 |
| STATE STREET CORP | 0.27% | 44,814 | +220% | 0% | $1,147,238 |
| MONIMUS CAPITAL MANAGEMENT, LP | 0.26% | 42,067 | 0% | 0.8% | $1,076,915 |
| NORTHERN TRUST CORP | 0.24% | 39,955 | +42% | 0% | $1,022,848 |
| MPM BIOIMPACT LLC | 0.24% | 39,665 | 0.17% | $1,015,424 | |
| Palumbo Wealth Management LLC | 0.21% | 34,798 | +86% | 0.29% | $890,829 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 12,244,439 | $313,500,808 | +$233,088,276 | $25.60 | 56 |
| 2025 Q2 | 3,148,479 | $57,049,319 | +$415,033 | $18.12 | 33 |
| 2025 Q1 | 3,175,639 | $30,358,304 | -$551,384 | $9.56 | 36 |
| 2024 Q4 | 3,185,761 | $50,270,587 | -$3,179,725 | $15.78 | 35 |
| 2024 Q3 | 1,026,987 | $15,540,749 | -$2,242,995 | $15.14 | 30 |
| 2024 Q2 | 1,175,256 | $16,110,171 | +$7,242,756 | $13.72 | 27 |
| 2024 Q1 | 647,283 | $8,609,474 | +$8,609,474 | $13.30 | 24 |